Literature DB >> 2619354

Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study.

H J Out1, P G de Groot, P Hasselaar, M dan Vliet, R H Derksen.   

Abstract

In 53 patients with systemic lupus erythematosus sequential blood samples obtained during a four year period (range 6-47 months) were screened for anticardiolipin antibodies (ACAs). Disease activity and treatment with prednisone were also assessed and related to ACA concentrations. During follow up only 21 patients for ACA IgG (40%) and 25 for ACA IgM (47%) remained in the ACA category (negative, low positive, high positive) found at the first sample taken at entrance. Marked increases from negative to high positive concentrations were sometimes seen and were not accompanied by typical events such as thrombosis or thrombocytopenia (the ACA syndrome). Shifts in ACA concentrations could not always be explained by changes in prednisone dose. Also, in patients with low dose prednisone treatment or none at all (n = 22) 10 patients (45%) changed ACA IgG category and 12 patients (55%) fluctuated in ACA IgM categories during follow up. As a consequence of the variability in ACA titres relations of ACAs with the ACA syndrome depended on the blood sample studied. In the second sample, randomly taken half way through follow up, no significant relations with the ACA syndrome could be found. Anticardiolipin antibody IgG was significantly associated with disease activity in 11/47 patients (23%) and in the group as a whole. During remission ACA IgG was significantly associated with the ACA syndrome, whereas during moderate/severe disease activity in the same patients that correlation was not significant. Anticardiolipin antibody IgM was much less influenced by disease activity, and in only 4/47 patients (9%) could a significant relation with disease activity be shown. Associations of ACA IgM with the ACA syndrome were significant during both lupus flares and remission.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2619354      PMCID: PMC1003942          DOI: 10.1136/ard.48.12.1023

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  Antiphospholipid antibodies in systemic lupus erythematosus: evidence of an association with positive Coombs' and hypocomplementemia.

Authors:  M Hazeltine; J Rauch; D Danoff; J M Esdaile; H Tannenbaum
Journal:  J Rheumatol       Date:  1988-01       Impact factor: 4.666

2.  IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes.

Authors:  M E Cronin; R M Biswas; C Van der Straeton; T A Fleisher; J H Klippel
Journal:  J Rheumatol       Date:  1988       Impact factor: 4.666

3.  Lupus anticoagulant, thrombosis, and fetal loss.

Authors:  D I Feinstein
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

4.  Anticardiolipin antibodies in patients with systemic lupus erythematosus.

Authors:  G Sturfelt; O Nived; R Norberg; R Thorstensson; K Krook
Journal:  Arthritis Rheum       Date:  1987-04

5.  The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus.

Authors:  W J Shergy; D W Kredich; D S Pisetsky
Journal:  J Rheumatol       Date:  1988-09       Impact factor: 4.666

6.  Anticardiolipin antibodies in patients with rheumatic diseases.

Authors:  J G Fort; F S Cowchock; J L Abruzzo; J B Smith
Journal:  Arthritis Rheum       Date:  1987-07

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus.

Authors:  K C Kalunian; J B Peter; H R Middlekauff; J Sayre; D G Ando; M Mangotich; B H Hahn
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

9.  Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

Authors:  R H Derksen; P Hasselaar; L Blokzijl; F H Gmelig Meyling; P G De Groot
Journal:  Ann Rheum Dis       Date:  1988-05       Impact factor: 19.103

10.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

View more
  12 in total

Review 1.  Antiphospholipid syndrome: laboratory testing and diagnostic strategies.

Authors:  Thomas L Ortel
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

2.  Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus.

Authors:  H J Out; M van Vliet; P G de Groot; R H Derksen
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

Review 3.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

4.  The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.

Authors:  Marie Hudson; Andrée-Laure Herr; Joyce Rauch; Carolyn Neville; Erika Chang; Reda Ibrahim; Chantal Séguin; Jeannine Kassis; Lambert Busque; Paul R Fortin
Journal:  J Rheumatol       Date:  2003-11       Impact factor: 4.666

5.  Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study.

Authors:  G D Sebastiani; G Passiu; M Galeazzi; F Porzio; U Carcassi
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

6.  Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes.

Authors:  Cecile M Yelnik; T Flint Porter; D Ware Branch; Carl A Laskin; Joan T Merrill; Marta M Guerra; Michael D Lockshin; Jill P Buyon; Michelle Petri; Lisa R Sammaritano; Mary D Stephenson; Mimi Y Kim; Jane E Salmon
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

7.  Antiphospholipid syndrome: five year follow up.

Authors:  R A Asherson; E Baguley; C Pal; G R Hughes
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 8.  Diagnosis and pathogenesis of CNS lupus.

Authors:  A P van Dam
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

Review 9.  Detection of autoantibodies in a point-of-care rheumatology setting.

Authors:  Konstantin N Konstantinov; Antonios Tzamaloukas; Robert L Rubin
Journal:  Auto Immun Highlights       Date:  2013-05-18

10.  Longitudinal Analysis of Anti-cardiolipin and Anti-β2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients.

Authors:  Martina Frodlund; Tomas Walhelm; Charlotte Dahle; Christopher Sjöwall
Journal:  Front Med (Lausanne)       Date:  2021-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.